Additional positive data from the successful Phase 3 VITESSE clinical trial for the VIASKIN Peanut Patch was presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting. The VITESSE study, the largest food allergy immunotherapy trial to date, assessed the VIASKIN Peanut Patch for treating peanut-allergic children aged 4 to 7 years. The study met its primary endpoint, with 46.6% of children in the VIASKIN Peanut arm meeting treatment responder criteria at 12 months, compared to 14.8% in the placebo arm, a statistically significant difference of 31.8% (95% CI: 24.5, 39.0%) that exceeded the prespecified 15% threshold. Approximately 82.8% of treated subjects increased their eliciting dose by at least one step at month 12, compared to 48% in the placebo group. Approximately 60.1% of treated subjects increased their eliciting dose by at least two steps at month 12, compared to 23.4% in the placebo group. Only 6.4% of treated subjects experienced a decrease in their eliciting dose, significantly lower than the 24% observed in the placebo group. The VIASKIN Peanut Patch was well tolerated, with the majority of treatment emergent adverse events being mild local application site reactions, consistent with previous Phase 3 studies.